WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
Wuxi Taclink Optoelectronics Technology (688205.SH): The preliminary inquiry transfer price is determined to be 135.29 yuan per share.
Liaoning Chengda Biotechnology (688739.SH): Benxi subsidiary passes drug GMP compliance inspection.
Rigol Technologies (688337.SH) has obtained approval from the China Securities Regulatory Commission for the issuance of its overseas listing shares (H shares).
Wuxi Taclink Optoelectronics Technology (688205.SH): The preliminary inquiry transfer price is determined to be 135.29 yuan per share.
Liaoning Chengda Biotechnology (688739.SH): Benxi subsidiary passes drug GMP compliance inspection.
Rigol Technologies (688337.SH) has obtained approval from the China Securities Regulatory Commission for the issuance of its overseas listing shares (H shares).
RECOMMEND
